« Return to News | CROs/Service Providers

Covance Revenue Up 8% in ‘09, Plans for 10% Growth in ‘10

Thursday, January 28, 2010 02:55 PM

Covance reported fourth-quarter revenue growth of 11% to $507 million, largely due to the positive impact of foreign exchange.

The CRO’s revenues grew 8% in 2009. Year-end revenues were $1.96 billion in 2009 compared with $1.83 billion in 2008. Operating margin was 11.3%.  Earnings per share were $2.73 for the year and $0.64 per diluted share for the fourth quarter.

Covance expects full-year revenue growth in 2010 to be 10% over 2009, and earnings per share to be in the range of $2.50 to $2.75.

Covance’s late-stage business, including central laboratory, phase II and III clinical development and commercialization services, jumped 26% in the fourth quarter to $282 million. Full-year net revenues grew 22% to $1.1 billion compared to $883.3 million in 2008.  

The company’s early-development segment did not fare as well, with revenues down 5% to $203 million from the fourth quarter last year.  Full year net revenues in this segment declined 6% to $792 million compared with $845 million in 2008.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.